Skip to content
The GLP-1 Verdict
Menu
Ranked #94 · Grade C

AmberHealth review

Direct-to-consumer telehealth provider offering among the lowest we track compounded GLP-1 pricing of the programmes we track.

Visit AmberHealth Assume we may earn a commission, at no cost to you. It never changes The Verdict Score, nor a word of this review.
Semaglutide
From $100/mo (starting dose, compounded)
Tirzepatide
From $175/mo (starting dose, compounded)
Coverage
All 50 states
Brand-name
Compounded only

The scorecard

AmberHealth scored on our six published factors. See the methodology.

Real-world results75/100
Price honesty64/100
Prescriber access90/100
Formulary choice82/100
Cancellation fairness56/100
Member support70/100

What we like

  • among the lowest we track monthly rates we track
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

The caveats

  • Limited public information on program details

The verdict

Best for: Budget-conscious shoppers. Direct-to-consumer telehealth provider offering among the lowest we track compounded GLP-1 pricing of the programmes we track.

Ranked #94 of 499 providers we have reviewed — for comparison, read our ruling on CoreAge Rx, our #1 pick. On the board it sits between Cora Health, 73/100 above and Amble at 73/100 below, with the Corsica Health ruling the next one down.

A grade C is a ranking, not an instruction to stop looking: the closest rivals to AmberHealth are ruled on the identical rubric, so the comparison is like for like. We have also ruled on it directly: CoreAge Rx vs AmberHealth goes to CoreAge Rx, 94/100 to 73/100.

Visit AmberHealth

Compare with other providers

All 498 other providers we've reviewed, in our overall ranking order.

Every other program we track (492)

Pricing, states and verification reflect AmberHealth's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on AmberHealth's site. Not medical advice; see our disclosure.

← Back to all rankings